Innovating Works

UCB PHARMA SA

Desconocido
Showing 1 to 20 of 35 results
Secreters: A new generation of microbial expression hosts and tools for the production of biotherapeutics and h... UCB PHARMA SA participó en un H2020 H2020-MSCA-ITN-2018 The ‘SECRETERS’ partnership aims to bring about a step change in the production of recombinant proteins, particularly Biotherapeutics and In...
2018-08-30 - 2023-06-30 | Financiado
ISOTOPICS: ISOTOPIC LABELING FOR DRUG INNOVATION UCB PHARMA SA participó en un H2020 H2020-MSCA-ITN-2015 Excessive attrition rates during clinical trials dramatically impact on Drug Discovery and Development (DDD). Absorption, Distribution, Meta...
2015-08-10 - 2019-12-31 | Financiado
EVOluTION: European Vascular Interventions and Therapeutic Innovation Network UCB PHARMA SA participó en un H2020 H2020-MSCA-ITN-2015 EVOluTION, a pioneering network within EU in view of its focus on endogenous protective mechanisms, is formed to provide training for 11 you...
2015-08-07 - 2020-03-31 | Financiado
ProteinFactory: Engineering of new generation protein secretion systems UCB PHARMA SA participó en un H2020 H2020-MSCA-ITN-2014 The market for recombinant proteins, including biopharmaceuticals, industrial enzymes and membrane proteins, is estimated to be about 78 bil...
2014-12-10 - 2018-12-31 | Financiado
eCHO Systems: Enhancing CHO by Mammalian Systems Biotechnology eCHO systems UCB PHARMA SA participó en un H2020 H2020-MSCA-ITN-2014 Chinese hamster (CHO) ovary cells are the production host for a +50 billion €/yr biopharmaceuticals market. Current CHO production platforms...
2014-12-05 - 2018-12-31 | Financiado
EBISC: European Bank for induced pluripotent Stem Cells UCB PHARMA SA participó en un FP6 EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, d...
2014-01-01 - 2017-12-31 | Financiado
EUC²LID: European Lead Factory UCB PHARMA SA participó en un FP6 The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as...
2013-01-01 - 2018-05-31 | Financiado
ABIRISK: Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the ri... UCB PHARMA SA participó en un FP6 The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique pane...
2012-03-01 - 2018-02-28 | Financiado
DDMORE: Drug Disease Model Resources UCB PHARMA SA participó en un FP6 Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD...
2011-03-01 - 2016-08-31 | Financiado
ETOX: Integrating bioinformatics and chemoinformatics approaches for the development of expert systems all... UCB PHARMA SA participó en un FP6 The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological pr...
2010-01-01 - 2016-12-31 | Financiado
MARCAR: bioMARkers and molecular tumor classification for non-genotoxic CARcinogenesis UCB PHARMA SA participó en un FP6 MARCAR aims to establish reliable early markers and molecular classification of tumors in non genotoxic carcinogenesis, applying a mechanism...
2010-01-01 - 2015-06-30 | Financiado
PHARMA-COG: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the earl... UCB PHARMA SA participó en un FP6 PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies...
2010-01-01 - 2015-12-31 | Financiado
U-BIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes UCB PHARMA SA participó en un FP6 RationaleThe inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this...
2009-10-01 - 2015-09-30 | Financiado
EUROPAIN: Understanding chronic pain and improving its treatment UCB PHARMA SA participó en un FP6 We will establish an international team of leading researchers and clinicians (EuroPain) to undertake multidisciplinary translational resear...
2009-10-01 - 2015-09-30 | Financiado
EU2P: European programme in Pharmacovigilance and Pharmacoepidemiology UCB PHARMA SA participó en un FP6 The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia...
2009-09-01 - 2016-06-30 | Financiado
PRO- ACTIVE: Physical Activity as a Crucial Patient Reported Outcome in COPD UCB PHARMA SA participó en un FP6 Physical activity (PA) is essential in maintaining optimal health in chronic diseases, including COPD.More physically active patients have l...
2009-09-01 - 2016-05-31 | Financiado
CCT-MicroIndus: Continuous Catalytic Transformations from optimization in MICRO systems to INDustrial production UCB PHARMA SA tramitó un FP7 This project is aiming at providing the training for 2 ESR in the framework of a integrated approach for heterogeneous catalysis in continuo...
Financiado
EUROPAIN: Understanding chronic pain and improving its treatment UCB PHARMA SA participó en un FP7 We will establish an international team of leading researchers and clinicians (EuroPain) to undertake multidisciplinary translational resear...
Financiado
ABIRISK: Anti Biopharmaceutical Immunization Prediction and analysis of clinical relevance to minimize the ri... UCB PHARMA SA participó en un FP7 The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique pane...
Financiado
ETOX: Integrating bioinformatics and chemoinformatics approaches for the development of expert systems all... UCB PHARMA SA participó en un FP7 The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological pr...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.